OLMA · Insider Trading
Olema Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by OLMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Jason O'Byrne | CHIEF FINANCIAL OFFICER | A | +650,000 deriv. | — |
| 2026-07-27 | Cyrus Harmon | Director | Sell | −25,000 | −$291.16K |
| 2026-06-23 | G. Walmsley Graham | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Prakash Raman | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Ian T Clark | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Gorjan Hrustanovic | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Cynthia M Butitta | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Andrew Rappaport | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Yi Larson | Director | A | +29,500 deriv. | — |
| 2026-06-23 | J. Scott Garland | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Sandra Horning | Director | A | +29,500 deriv. | — |
| 2026-06-23 | Cyrus Harmon | Director | A | +29,500 deriv. | — |
| 2026-06-23 | BVF GP HOLDINGS LLC | Director | A | — | — |
| 2026-04-29 | Prakash Raman | Director | A | +27,061 deriv. | — |
| 2026-03-05 | Shawnte Mitchell | CHIEF LEGAL OFFICER | MIXED | — | −$776.70K |
| 2026-02-17 | Sasha Lu Austin | VP of Finance and Controller | A | +11,700 | — |
| 2026-02-04 | Shawnte Mitchell | CHIEF LEGAL OFFICER | A | +276,250 deriv. | — |
| 2026-02-04 | Sean Bohen | PRESIDENT AND CEO | A | +1,125,000 deriv. | — |
| 2026-02-04 | Naseem Zojwalla | CHIEF MEDICAL OFFICER | A | +356,250 deriv. | — |
| 2026-02-04 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | A | +356,250 deriv. | — |
| 2026-01-21 | Cyrus Harmon | Director | Sell | −10,000 | −$268.80K |
| 2026-01-16 | Cyrus Harmon | Director | Sell | −3,489 | −$101.60K |
| 2026-01-15 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | Sell | −103,822 | −$2.98M |
| 2026-01-14 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | MIXED | −10,000 | −$2.62M |
| 2025-12-30 | Sean Bohen | President and CEO | G | −8,500 | — |
| 2025-12-29 | Cyrus Harmon | Director | Sell | −2,881 | −$82.19K |
| 2025-12-23 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | MIXED | −60,000 | −$1.55M |
| 2025-12-23 | Naseem Zojwalla | Chief Medical Officer | MIXED | −129,509 | −$5.87M |
| 2025-12-23 | Ian T Clark | Director | MIXED | — | −$6.65M |
| 2025-12-09 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | G | −75,000 | — |
| 2025-12-01 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | G | −225,000 | — |
| 2025-11-25 | Andrew Rappaport | Director | MIXED | — | +$13.99K |
| 2025-09-18 | Cyrus Harmon | Director | Sell | −25,000 | −$204.84K |
| 2025-06-13 | J. Scott Garland | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Cynthia M Butitta | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Ian T Clark | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Cyrus Harmon | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Yi Larson | Director | A | +24,150 deriv. | — |
| 2025-06-13 | G. Walmsley Graham | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Gorjan Hrustanovic | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Andrew Rappaport | Director | A | +24,150 deriv. | — |
| 2025-06-13 | Sandra Horning | Director | A | +24,150 deriv. | — |
| 2025-06-13 | BVF INC/IL | Director | A | — | — |
| 2025-05-13 | G. Walmsley Graham | Director | — | — | — |
| 2025-03-03 | Naseem Zojwalla | CHIEF MEDICAL OFFICER | A | +205,000 deriv. | — |
| 2025-03-03 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | A | +205,000 deriv. | — |
| 2025-03-03 | Shawnte Mitchell | CHIEF LEGAL OFFICER | A | +450,000 deriv. | — |
| 2025-03-03 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | A | +320,000 deriv. | — |
| 2025-03-03 | Sean Bohen | PRESIDENT AND CEO | A | +650,000 deriv. | — |
| 2025-01-14 | BVF I GP LLC | Director | D | −420,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bain Capital Life Sciences Opportunities IV, L.P. | 10%+ Owner | 7,800,000 | $55.54M |
| BVF INC/IL | Director | 2,103,522 | $14.98M |
| BVF GP HOLDINGS LLC | Director | 2,103,522 | $14.98M |
| G. Walmsley Graham | Director | 1,800,000 | $12.82M |
| Cyrus Harmon | Director | 819,798 | $5.84M |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | 687,807 | $4.90M |
| BIOTECHNOLOGY VALUE FUND L P | Director | 470,266 | $3.35M |
| BVF I GP LLC | Director | 447,526 | $3.19M |
| Andrew Rappaport | Director | 421,833 | $3.00M |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | 239,727 | $1.71M |
| Sean Bohen | PRESIDENT AND CEO | 237,650 | $1.69M |
| Ian T Clark | Director | 209,690 | $1.49M |
| Naseem Zojwalla | CHIEF MEDICAL OFFICER | 146,815 | $1.05M |
| Cynthia M Butitta | Director | 83,876 | $597.20K |
| Sasha Lu Austin | VP of Finance and Controller | 16,188 | $115.26K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OLMA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.